<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185418</url>
  </required_header>
  <id_info>
    <org_study_id>CBIRB0226-22</org_study_id>
    <nct_id>NCT01185418</nct_id>
  </id_info>
  <brief_title>Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer</brief_title>
  <official_title>Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer: a Double-blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, Amisulpride, Risperidone and Aripiprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the negative symptoms and cognitive function after
      administration of antipsychotics in healthy volunteer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms assessment by objective and subjective rating scale</measure>
    <time_frame>2 hour</time_frame>
    <description>VAS - mental sedation (alert-drowsy, muzzy-clear headed, mentally slow-quick witted, attentive-dreamy), physical sedation (strong-feeble, well coordinated-clumsy, lethargic-energetic, incompetent-proficient), tranquilization (calm-excited, contented-discontented, troubled-tranquil, tense-relaxed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms assessment by objective and subjective rating scales &amp; CNT</measure>
    <time_frame>4hour</time_frame>
    <description>SANS-alogia and blunted affect, SDSS-Subjective Deficit Syndrome Scale ,self-report questionnaire to measure lack of energy, blunted affect, and difficulty in or altered thinking, consisting of 19 questions, with the scales from 0 to 4 NIDSS-consists of 20 items with a five-point Likert scale (from 0, none to 4, severe) and has three subscales: avolition (five items), blunted affect (five items), and cognition (ten items), CNT-computerized neuropsychological test, VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms assessment by objective and subjective rating scales</measure>
    <time_frame>24hour</time_frame>
    <description>SANS, SDSS, NIDSS, VAS SANS-alogia and blunted affect, SDSS-Subjective Deficit Syndrome Scale ,self-report questionnaire to measure lack of energy, blunted affect, and difficulty in or altered thinking, consisting of 19 questions, with the scales from 0 to 4 NIDSS-consists of 20 items with a five-point Likert scale (from 0, none to 4, severe) and has three subscales: avolition (five items), blunted affect (five items), and cognition (ten items), VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms assessment by objective rating scale</measure>
    <time_frame>4hour</time_frame>
    <description>BARS-Barnes akathisia rating scale (BAS), consisting of 4 items, identifies drug-induced akathisia and measures severity, SAS-Simpson-angus scale (SAS), consisting of 10 items, measures neuroleptic induced parkinsonism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms assessment by objective rating scale</measure>
    <time_frame>24hour</time_frame>
    <description>BARS, SAS</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Normal Volunteers</condition>
  <arm_group>
    <arm_group_label>risperidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>haloperidol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>amisulpride</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>lactose</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <arm_group_label>risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole</intervention_name>
    <arm_group_label>aripiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol</intervention_name>
    <arm_group_label>haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amisulpride</intervention_name>
    <arm_group_label>amisulpride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactose</intervention_name>
    <arm_group_label>lactose</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Recruited volunteers among normal adults aged from 18 to 38 who responded advertisements
        for research subjects. Then selected subjects from the applicants using various screening
        tests - physical and neurological examination including confirming vital signs after
        examining physical health and sleep habits of volunteers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-38 years and meet no DSM-IV diagnostic criteria as assessed by using the
             Structured Clinical Interview for DSM-IV, research version.

        Exclusion Criteria:

          -  1) anyone who participated in other clinical trials within 30 days from the start of
             this clinical trial or is currently participating in one,

          -  2) anyone who has progressive disease or in unstable medical condition unfit for the
             trial,

          -  3) anyone who has been diagnosed in psychiatric terms in the past, depends on
             psychotropic substance, or has overdosed or depended on the substance or alcohol
             (except for coffee or tobacco) within 1 month from the trial start,

          -  4) anyone who is suicidal or highly probable of suicides, or

          -  5) anyone who has test results considered clinically meaningful
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk national university hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <last_update_submitted>August 19, 2010</last_update_submitted>
  <last_update_submitted_qc>August 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Young Chul Chung/Professor of Psychiatry</name_title>
    <organization>Chonbuk National University Hospital, Jeonju, Korea</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

